879 related articles for article (PubMed ID: 28065838)
1. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
[TBL] [Abstract][Full Text] [Related]
2. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
[TBL] [Abstract][Full Text] [Related]
3. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
Heimall J; Puck J; Buckley R; Fleisher TA; Gennery AR; Neven B; Slatter M; Haddad E; Notarangelo LD; Baker KS; Dietz AC; Duncan C; Pulsipher MA; Cowan MJ
Biol Blood Marrow Transplant; 2017 Mar; 23(3):379-387. PubMed ID: 28068510
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
5. Matched sibling donor hematopoietic stem cell transplantation for thalassemia.
Issaragrisil S; Kunacheewa C
Curr Opin Hematol; 2016 Nov; 23(6):508-514. PubMed ID: 27518930
[TBL] [Abstract][Full Text] [Related]
6. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-Thalassemia.
Chaudhury S; Ayas M; Rosen C; Ma M; Viqaruddin M; Parikh S; Kharbanda S; Chiang KY; Haight A; Bhatia M; Guilcher G; Thompson A; Shenoy S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1695-1700. PubMed ID: 28627425
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.
Bernaudin F; Pondarré C; Galambrun C; Thuret I
Adv Exp Med Biol; 2017; 1013():89-122. PubMed ID: 29127678
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
Horan JT; Liesveld JL; Fenton P; Blumberg N; Walters MC
Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
[TBL] [Abstract][Full Text] [Related]
12. [Results of hematopoietic stem cell transplantation in hemoglobinopathies: thalassemia major and sickle cell disease].
Hladun R; Elorza I; Olivé T; Dapena JL; Llort A; Sánchez de Toledo J; Díaz de Heredia C
An Pediatr (Barc); 2013 Aug; 79(2):75-82. PubMed ID: 23402775
[TBL] [Abstract][Full Text] [Related]
13. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
[TBL] [Abstract][Full Text] [Related]
14. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic cellular gene therapy for hemoglobinopathies.
Gaziev J; Lucarelli G
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1145-63. PubMed ID: 21075285
[TBL] [Abstract][Full Text] [Related]
16. Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.
Walters MC; De Castro LM; Sullivan KM; Krishnamurti L; Kamani N; Bredeson C; Neuberg D; Hassell KL; Farnia S; Campbell A; Petersdorf E
Biol Blood Marrow Transplant; 2016 Feb; 22(2):207-211. PubMed ID: 26500093
[TBL] [Abstract][Full Text] [Related]
17. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.
Dietz AC; Mehta PA; Vlachos A; Savage SA; Bresters D; Tolar J; Boulad F; Dalle JH; Bonfim C; de la Fuente J; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP
Biol Blood Marrow Transplant; 2017 May; 23(5):726-735. PubMed ID: 28115275
[TBL] [Abstract][Full Text] [Related]
18. Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies.
Malhotra M; Shenoy S
Transfus Apher Sci; 2022 Oct; 61(5):103554. PubMed ID: 36096996
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow transplantation in sickle cell anemia.
Hoppe CC; Walters MC
Curr Opin Oncol; 2001 Mar; 13(2):85-90. PubMed ID: 11224704
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape.
Kassim AA; Sharma D
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):259-266. PubMed ID: 28641096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
